0001209191-17-025181.txt : 20170404 0001209191-17-025181.hdr.sgml : 20170404 20170404174302 ACCESSION NUMBER: 0001209191-17-025181 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170403 FILED AS OF DATE: 20170404 DATE AS OF CHANGE: 20170404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cascadian Therapeutics, Inc. CENTRAL INDEX KEY: 0001412067 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 260868560 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2601 FOURTH AVENUE STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: (206) 801-2100 MAIL ADDRESS: STREET 1: 2601 FOURTH AVENUE STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: Oncothyreon Inc. DATE OF NAME CHANGE: 20070927 FORMER COMPANY: FORMER CONFORMED NAME: Biomira CORP DATE OF NAME CHANGE: 20070911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Azelby Robert CENTRAL INDEX KEY: 0001656998 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33882 FILM NUMBER: 17739932 MAIL ADDRESS: STREET 1: 307 WESTLAKE AVE. NORTH, STE 300 CITY: SEATTLE STATE: WA ZIP: 98109 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-04-03 0 0001412067 Cascadian Therapeutics, Inc. CASC 0001656998 Azelby Robert C/O CASCADIAN THERAPEUTICS, INC. 2601 FOURTH AVE., SUITE 500 SEATTLE WA 98121 1 0 0 0 Restricted Stock Unit (RSU) 2017-04-03 4 A 0 12437 0.00 A Common Stock 12437 12437 D Approximately 75% of the RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSU. 100% vests on the one-year anniversary of the Transaction Date, subject to acceleration under certain circumstances. /s/ Julia M. Eastland as attorney-in-fact for Robert Azelby 2017-04-04